Following the stratified analysis based on WHO grades (including grade II, III, and IV) in CGGA-325 cohort, it was found that the glioma patients with high expression of each member of LOXs displayed shorter overall survival except that no statistical significance was observed following the analysis of distinct LOX or LOXL1 expressions in the WHO grade II glioma patients (Figures 4B,E,H,K,N). This evidence concerns the gene LOX and central nervous system cancer.